Skip to main content

Table 7 Back-transformed LS means PCV2 SERELISA values by treatment and study day for studies B and C

From: A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines

Study

Treatment Group (T)

Day of Study

− 1

21

24

28 or 29

31

35

38

42

B

T01

0.809

0.884

0.839

0.882

0.842

0.598

0.605

0.560

B

T02

0.808

0.852

0.804

0.478*

0.357*

0.203*

0.196*

0.158*

B

T03

0.805

0.733*

0.722*

0.329*

0.290*

0.186*

0.160*

0.130*

C

T01

0.844

0.877

ND

ND

ND

ND

ND

0.479

C

T02

0.867

0.784*

ND

ND

ND

ND

ND

0.202**

C

T03

0.862

0.709*

ND

ND

ND

ND

ND

0.136**

  1. Value is significantly different from T01 saline controls (*P ≤ 0.0013, ** P ≤ 0.05) within the column (Day of Study; Study Day 0 corresponded to the day of vaccination). All values on Days − 1 and 21 are considered negative based on the assay positive/negative cut-off. SERELISA: the lower the S/Nc SERELISA value the more positive the value is and the higher the antibody level.
  2. ND: not determined.
Back to article page

Veterinary Research

ISSN: 1297-9716